Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that its management team will participate in two upcoming investor conferences in May 2026. The company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.'s Annual Virtual Healthcare Conference on May 20. These presentations provide an opportunity for investors to hear directly from Tonix's leadership about its recent commercial milestones and pipeline progress.
The company's flagship product, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), recently received approval as the first new treatment for fibromyalgia in over 15 years. Tonix is leveraging its CNS commercial infrastructure to support TONMYA along with its acute migraine products, Zembrace SymTouch and Tosymra. Beyond fibromyalgia, Tonix is conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder, expanding its therapeutic reach into areas of high unmet medical need.
Tonix's pipeline also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease. In immunology, the company is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs underscore Tonix's commitment to addressing significant health challenges through innovative science.
Investors can access the full press release and additional information through the company's newsroom at https://ibn.fm/TNXP. The conference participation aligns with Tonix's strategy to communicate its progress and engage with the investment community, highlighting its integrated commercial platform and diverse pipeline. As a fully integrated biotechnology company, Tonix continues to build on its recent approval and advance its portfolio to meet patient needs.
